Arecor receives £2.8 million grant award from Innovate UK

Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it  has  been  awarded  a  £2.8 million grant from Innovate UK to support the Phase II development of AT247, its ultra-rapid acting insulin product candidate which is based on Arecor’s proprietary Arestat™ technology platform.

Arecor logo

Sarah Howell, Chief Executive Officer of Arecor, said:"We are proud that Innovate UK has, through their thorough technical and commercial review  process, chosen to invest  in our research from across the very best  of  British  science. Diabetes  remains  a  significant  and  growing health problem throughout  the  world.  AT247, the lead product from our pipeline of next generation rapid insulins is focused on transforming the lives of people living with Type 1 diabetes through its potential to enable greater glucose control.  This control is critical in helping patients to avoid hyper-and hypo-glycaemia events, improve time in range and reduce overall  disease  complications.   

"The substantial  grant we  are  announcing  today provides  additional  non-dilutive funding to support and accelerate AT247’s Phase II development.”

Dr Thomas Pieber, PI for the Phase II study at Medical University of Graz said: “AT247 is a very promising candidate in the pursuit for next generation insulins designed to improve postprandial glycaemic control and flexibility  of  insulin  dosing. The Phase  II  development  programme  will  build on the early  clinical  evidence that AT247 has highly favourable pharmacokinetic properties1 and may facilitate a fully closed loop artificial pancreas, a potentially life changing treatment option for people living with diabetes.”    

AT247, a novel proprietary formulation of insulin, has been designed to accelerate insulin absorption, post injection, to achieve more effective and controlled management of blood glucose levels. The development programme, supported by the grant, will include  a Phase  II clinical trial to compare the glycaemic control, safety  and  tolerability of  AT247 with  Fiasp® when  administered  by  insulin  pump  over an  extended  period. Continuous glucose monitoring will allow the assessment of time spent with blood glucose level in a healthy range, the  control  of which  is crucial for  avoiding episodes  of  hyper-and  hypo-glycaemia and  delivering positive long term health outcomes for people with Type 1 Diabetes.This Phase II clinical trial is expected to commence  in H12022 and  is  part of  an  extensive development programme  designed  to  demonstrate  the benefits of AT247 as a potentially best-in-class ultra-rapid acting insulin.

Despite   significant   advances   in   treatment   options, 79%   of   people   with   diabetes   live   with   severe complications due to time spent outside of their target blood glucose range. It has been shown that blood glucose control and time in range can be improved when patients are using an automated insulin delivery system, where blood glucose is continuously measured, while an algorithm calculates insulin requirements based on real-time blood glucose which is then automatically delivered by a pump.

AT247 has the potential to be an ideal pump insulinenabling a closed loop artificial pancreas for patients with Type I diabetes to be realised.


(1) Svehlikova, E; Mursic, I; Augustin, T; Magnes, C; Gerring, D; Jezek, J; Schwarzenbacher, D; Ratzer, M; Wolf, M; Howell, S; Zakrzewski, L; Urschitz, M;  Tschapeller,  B;  Gatschelhofer,  C;  Feichtner,  F;  Lawrence,  F;  Pieber,  TR,  2020  Pharmacokinetics  and  Pharmacodynamics  of  Three  Different Formulations of Insulin Aspart: A Randomized, Double-blind, Crossover Study in Men with Type 1 Diabetes. Diabetes Care. 2021 Feb;44(2):448-455. doi: 10.2337/dc20-1017


Read more

Looking for something specific?